A study of CTX-10726 for certain advanced cancers
Part of Cancer, Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug called CTX-10726 in people with advanced kidney, liver, stomach, or uterine cancer that has not responded to standard treatments. The goal is to see if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of four types of advanced cancer: kidney cancer (with a clear cell type), liver cancer, stomach/esophageal cancer, or uterine (endometrial) cancer that has gotten worse after at least two doses of immunotherapy (PD-1/PD-L1 treatment).
- You must have tried standard therapy and it no longer works, or no standard therapy exists for your cancer.
- You must have measurable disease (tumors that can be seen on scans) that hasn't been treated with radiation.
- You must be generally active (ECOG performance status 0-1).
- Your organs (bone marrow, liver, kidneys, heart) must be working well enough based on blood tests and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This trial tests an experimental oral drug called MTX-531 in people with certain advanced cancers that have not responded to standard treatments. The study aims to see if the drug shrinks tumors or slows their growth, and to find the best dose.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
This study tests an immunotherapy drug (CTX-471) for people with a specific type of advanced neuroendocrine tumor that has grown after chemotherapy. The goal is to see if the drug can help shrink or control the tumor.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.